Wilsonian Disease (Sarcoidosis) – A Comprehensive Guide

Overview

Wilsonian disease is another name for sarcoidosis, a systemic inflammatory disorder characterized by the formation of non‑caseating granulomas (tiny clusters of immune cells) in multiple organs. The disease most commonly involves the lungs and lymph nodes, but virtually any organ—including the skin, eyes, heart, and nervous system—can be affected.

Who it affects

• Age: Typically diagnosed between 20–40 years, but can occur at any age.
• Sex: Slight female predominance (≈ 60 % of cases).
• Race/Ethnicity: Higher incidence in African‑American, Scandinavian, and Caribbean populations. In the United States, African‑American women have a prevalence up to three‑fold higher than White women (≈ 35 per 100,000 vs. 12 per 100,000) [CDC].

Overall prevalence worldwide ranges from 10–20 cases per 100,000 people, with regional “hot spots” in the United Kingdom, Sweden, and the United States.

Symptoms

Symptoms vary widely based on the organs involved and may be mild, intermittent, or severe. Below is a comprehensive list:

General / Constitutional

• Fatigue – persistent tiredness not relieved by rest.
• Fever – low‑grade (often < 38 °C) and intermittent.
• Weight loss – unintended loss of > 5 % body weight over 6 months.
• Night sweats – especially in advanced disease.

Respiratory

• Dry cough – non‑productive, often worse at night.
• Shortness of breath (dyspnea) – on exertion or at rest in severe cases.
• Chest pain – pleuritic or tight‑ness due to lymphadenopathy.
• Wheezing or crackles heard on exam.

Skin

• Lupus pernio – violaceous, raised plaques on the nose, cheeks, or ears.
• Erythema nodosum – tender red nodules, usually on shins.
• Maculopapular rash – flat or raised red spots, often on the trunk.

Ocular

• Redness, pain, tearing (uveitis).
• Photophobia – sensitivity to light.
• Blurred vision – may indicate posterior segment involvement.

Cardiac

• Palpitations or irregular heartbeat.
• Chest discomfort mimicking angina.
• Syncope – fainting due to conduction block.

Neurological

• Facial nerve palsy (Bell’s palsy).
• Headaches or seizures.
• Peripheral neuropathy – tingling or numbness.

Other

• Joint pain or swelling – often non‑erosive.
• Dry mouth – due to salivary gland involvement.

Because the clinical picture can mimic infections, lymphoma, or autoimmune disorders, a thorough evaluation is essential.

Causes and Risk Factors

The exact trigger for sarcoidosis remains unknown, but research points to an abnormal immune response to an unidentified antigen in genetically susceptible individuals.

• Genetic predisposition: Certain HLA alleles (e.g., HLA‑DRB1*03, HLA‑DRB1*04) increase risk [NIH].
• Environmental exposures:
  • Inorganic dusts (silica, talc).
  • Organic antigens (bacterial proteins, mycobacteria, propionibacteria).
  • Occupational exposures (metalworking, farming).
• Infectious agents: Some studies suggest a link with Mycobacterium or Propionibacterium acnes, but evidence is not definitive.
• Age and sex: Young adults, especially women, are more commonly affected.
• Race/ethnicity: African‑American and Scandinavian ancestry confer higher incidence.

Diagnosis

Diagnosing sarcoidosis is a step‑wise process that combines clinical suspicion, imaging, histology, and exclusion of other diseases.

Step 1 – Clinical Evaluation

• Detailed medical history (symptom chronology, occupational exposure, family history).
• Comprehensive physical exam focusing on lungs, skin, eyes, heart, and neurologic system.

Step 2 – Imaging

• Chest X‑ray: Bilateral hilar lymphadenopathy is classic.
• High‑Resolution CT (HRCT): Detects parenchymal nodules, fibrosis, and ground‑glass opacities.
• Cardiac MRI or PET‑CT: Useful for cardiac or systemic active disease.

Step 3 – Laboratory Tests

• Serum angiotensin‑converting enzyme (ACE): Elevated in ~60 % of active cases, but non‑specific.
• Calcium studies: Hypercalcemia or hypercalciuria can occur due to increased vitamin D activation.
• Inflammatory markers: ESR, CRP may be modestly raised.

Step 4 – Tissue Biopsy

Definitive diagnosis requires demonstration of non‑caseating granulomas with exclusion of infectious causes (e.g., TB, fungal). Common biopsy sites:

• Transbronchial lung biopsy (via bronchoscopy).
• Mediastinal lymph node sampling (endobronchial ultrasound‑guided).
• Skin lesions or peripheral lymph nodes.

Step 5 – Exclusion of Mimics

Additional tests may be ordered to rule out:
– Tuberculosis (AFB stain, cultures, Interferon‑γ release assay).
– Fungal infections (histoplasma, coccidioides serology).
– Lymphoma (PET‑CT, flow cytometry).

Treatment Options

Treatment is individualized based on organ involvement, disease severity, and impact on quality of life. Approximately one‑third of patients have self‑limited disease and require only observation.

1. Observation (Watchful Waiting)

• Indicated for asymptomatic stage I pulmonary disease (bilateral hilar lymphadenopathy only).
• Regular follow‑up with pulmonary function tests (PFTs) and imaging every 6–12 months.

2. First‑Line Pharmacologic Therapy

• Corticosteroids (prednisone 20–40 mg/day) – mainstay for symptomatic or progressive disease.
  Side‑effects*: weight gain, hypertension, glucose intolerance, osteoporosis – therefore use lowest effective dose and taper when possible.

3. Steroid‑Sparing Agents

Used when long‑term steroids are contraindicated or cause adverse effects.

• Methotrexate 10–25 mg weekly (first‑line steroid‑sparing).
• Azathioprine 2–2.5 mg/kg/day.
• Mycophenolate mofetil 1–1.5 g twice daily.

4. Biologic Therapy

Reserved for refractory disease.

• Infliximab (anti‑TNF‑α) – effective for pulmonary, cardiac, and neurologic sarcoidosis.
• Adalimumab – alternative when infliximab not tolerated.

5. Organ‑Specific Interventions

• Ocular disease: Topical steroids, systemic steroids, or peri‑ocular injections; referral to ophthalmology.
• Cardiac sarcoidosis: Implantable cardioverter‑defibrillator (ICD) for high‑risk arrhythmias; anti‑arrhythmic meds.
• Neurologic disease: High‑dose IV methylprednisolone followed by oral taper; consider methotrexate or infliximab.

6. Lifestyle & Supportive Measures

• Smoking cessation – improves lung outcomes.
• Vitamin D & calcium monitoring – avoid hypercalcemia.
• Regular exercise (aerobic & strength) to maintain lung capacity and bone health.
• Psychological support – chronic disease can impact mental health; consider counseling.

Living with Wilsonian Disease (Sarcoidosis)

Monitoring

• Pulmonary function tests (FVC, DLCO) every 6–12 months.
• Serum calcium and ACE levels as markers of activity.
• Annual ophthalmology exam, even if asymptomatic.
• Cardiac evaluation (ECG, Holter monitor) if any cardiac symptoms.

Daily Management Tips

1. Medication adherence – set alarms or use pill boxes.
2. Vaccinations – stay up‑to‑date on influenza, COVID‑19, pneumococcal, and hepatitis B (especially if on immunosuppressants).
3. Sun protection – some patients develop photosensitivity; use SPF 30+ sunscreen.
4. Nutrition – balanced diet rich in calcium and vitamin D (unless hypercalcemia is present). Limit high‑oxalate foods if kidney stones have occurred.
5. Stress reduction – yoga, meditation, or gentle walks can help with fatigue.
6. Travel planning – carry a medication list, emergency steroids, and a letter from your physician.

Support Resources

• Sarcoidosis Foundation
• Local patient support groups (often hosted through hospitals or online forums).
• Clinical trial registries (ClinicalTrials.gov) for emerging therapies.

Prevention

Because the precise cause is unknown, primary prevention is limited. However, risk reduction strategies include:

• Avoiding known occupational exposures such as silica dust, metal fumes, and organic dusts.
• Maintaining good respiratory hygiene – use masks when working in dusty environments.
• Early medical evaluation of persistent cough, unexplained skin lesions, or eye irritation.

Complications

If left untreated or inadequately controlled, sarcoidosis can lead to serious, sometimes irreversible, damage.

• Pulmonary fibrosis – chronic scarring leading to severe dyspnea and reduced life expectancy.
• Cardiac conduction block, ventricular arrhythmias, or heart failure.
• Ocular complications – glaucoma, cataracts, or permanent vision loss.
• Neurologic deficits – cranial nerve palsies, seizures, or spinal cord compression.
• Hypercalcemia – can cause kidney stones, nephrocalcinosis, or neuropsychiatric symptoms.
• Psychosocial impact – depression, anxiety, and reduced work productivity.

When to Seek Emergency Care

References

1. Mayo Clinic. Sarcoidosis. https://www.mayoclinic.org. Accessed June 2026.
2. Centers for Disease Control and Prevention (CDC). Sarcoidosis prevalence and demographics. https://www.cdc.gov. Accessed June 2026.
3. National Institutes of Health (NIH). Genetic factors in sarcoidosis. https://www.nih.gov. 2025.
4. Cleveland Clinic. Sarcoidosis treatment options. https://my.clevelandclinic.org. Updated 2024.
5. World Health Organization (WHO). Sarcoidosis – global health overview. https://www.who.int. 2024.